An open label clinical trial of complement inhibition in multifocal motor neuropathy

Journal of the Peripheral Nervous System

Volumn 16, Issue 2, 2011, Pages 84-91

  Fitzpatrick, Amanda M ^a,b   Mann, Cameron A ^b   Barry, Sarah ^c   Brennan, Katie ^a,b   Overell, James R ^b   Willison, Hugh J ^a,b,c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Clinical trial; Complement; Intravenous immunoglobulin; Membrane attack complex; Multifocal motor neuropathy; Therapy

Indexed keywords

ECULIZUMAB; IMMUNOGLOBULIN; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD SYMPTOM; COMPLEMENT INHIBITION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELECTROPHYSIOLOGY; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; MOTOR NEUROPATHY; MOTOR PERFORMANCE; MULTIFOCAL MOTOR NEUROPATHY; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RASH; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME; VOMITING; DEMYELINATING DISEASE; MIDDLE AGED; POLYNEUROPATHY;

AGED; ANTIBODIES, MONOCLONAL; COMPLEMENT INACTIVATING AGENTS; DEMYELINATING DISEASES; ELECTROPHYSIOLOGY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; POLYNEUROPATHIES;

EID: 80052455879     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2011.00328.x     Document Type: Article

References (15)

1. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, Cochrane L, Bullens RW, Molenaar PC, Conner J, Willison HJ (1999). Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 6: 697-708. (Pubitemid 29536355)
2. Greenshields KN, Halstead SK, Zitman FM, Rinaldi S, Brennan KM, O'Leary C, Chamberlain LH, Easton A, Roxburgh J, Pediani J, Furukawa K, Furukawa K, Goodyear CS, Plomp JJ, Willison HJ (2009). The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 3:595-610.
3. Halstead SK, O'Hanlon GM, Humphreys PD, Morrison DB, Morgan BP, Todd AJ, Plomp JJ, Willison HJ (2004). Antidisialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127:2109-2123. (Pubitemid 39150268)
4. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G,Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006). The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 12:1233-1243. (Pubitemid 44427447)
5. Joint Task Force of the EFNS and the PNS (2006). European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 11:1-8.
6. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N (2001). Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebocontrolled study. Brain 124:145-153. (Pubitemid 32055996)
7. O'Hanlon GM, Humphreys PD, Goldman RS, Halstead SK, Bullens RW, Plomp JJ, Ushkaryov Y, Willison HJ (2003). Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain 126:2497-2509. (Pubitemid 37314438)
8. Orbach H, Katz U, Sherer Y, Shoenfeld Y (2005). Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 3:173-184. (Pubitemid 43041668)
9. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L (2007). Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 11:1256-1264. (Pubitemid 350076509)
10. Santoro M, Uncini A, Corbo M, Staugaitis SM, Thomas FP, Hays AP, Latov N (1992). Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol 4:385-390.
11. Terenghi F, Cappellari A, Bersano A, Carpo M, Barbieri S, Nobile-Orazio E (2004). How long is IVIg effective inmultifocal motor neuropathy? Neurology 4:666-668. (Pubitemid 38252820)
12. van Schaik IN, Bossuyt PM, Brand A, Vermeulen M (1995). Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis. Neurology 8:1570-1577.
13. van Schaik IN, Bouche P, Illa I, Leger JM, Van den Bergh P, Cornblath DR, Evers EM, Hadden RD, Hughes RA, Koski CL, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA (2006). European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 8:802-808. (Pubitemid 44124675)
14. Willison HJ, Veitch J, Swan AV, Baumann N, Comi G, Gregson NA, Illa I, Zielasek J, Hughes RA (1999). Inter-laboratory validation of an ELISA for the determination of serum antiganglioside antibodies. Eur J Neurol 1:71-77. (Pubitemid 29092362)
15. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, Ueda S, Kasama T, Ohnishi A, Hayashi S, Takahashi H, Kamijo M, Hirata K (2001). Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 6:712-720. (Pubitemid 32530237)